Main Article Content
Background. The search and study of new risk factors for the development and progression of diabetic retinopathy (DRP) and their modifying influence on the components of metabolic syndrome in type 2 diabetes mellitus (T2DM) remain relevant. The purpose was to conduct a comparative evaluation of the impact of certain DRP development factors on indices of lipid metabolism in metabolic syndrome. Materials and methods. The research was carried out in 64 patients (95 eyes) with T2DM, metabolic syndrome and DRP (males and females, average age 61.55 ± 2.37 years, average duration of diabetes 11.23 ± 2.11 years, average level of HbA1c 9.89 ± 0.78 %, average body mass index 34.55 ± 3.75 kg/m2), who were divided into 3 groups depending on the stage of DRP. Results. Results had showed that the following factors have modifying influence on the level of total cholesterol in the blood of patients with T2DM and DRP: age of patients (under 60 years), duration of diabetes (less than 10 years), decompensation of carbohydrates metabolism — for the 3rd stage of DRP, features of therapy for T2DM (oral hypoglycemic drugs) — for the 2nd stage of DRP; on the level of low-density lipoprotein cholesterol: younger age of patients, decompensation of diabetes — for the 3rd stage of DRP, features of hypoglycemic therapy (insulin therapy), shorter duration of diabetes — for the 2nd stage of DRP; on the level of triglycerides: age of patients (under 60 years), duration of diabetes (less than 10 years) and insulin therapy — for the 1st and 3rd stages of DRP. Conclusions. It is concluded that features of hypoglycemic therapy can be a new modifying factor for the risk of DRP progression.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Arnold E, Rivera JC, Thebault S, et al. High levels of serum prolactin protect against diabetic retinopathy by increasing ocular vasoinhibins. Diabetes. 2010 Dec;59(12):3192-7. doi: 10.2337/db10-0873.
VADT Study Group; Azad N, Agrawal L, Emanuele NV, et al. Association of PAI-1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2014 Feb;37(2):501-506. doi: 10.2337/dc13-1193.
Dong L, Bai J, Jiang X, et al. The gene polymorphisms of IL-8(-251T/A) and IP-10(-1596C/T) are associated with susceptibility and progression of type 2 diabetic retinopathy in northern Chinese population. Eye (Lond). 2017 Apr;31(4):601-607. doi: 10.1038/eye.2016.287.
Hughes JM, Brink A, Witmer AN, Hanraads-de Riemer M, Klaassen I, Schlingemann RO. Vascular leucocyte adhesion molecules unaltered in the human retina in diabetes. Br J Ophthalmol. 2004 Apr; 88(4): 566–572. doi: 10.1136/bjo.2003.021204.
Nguyen TT, Alibrahim E, Islam FM, et al. Inflammatory, hemostatic, and other novel biomarkers for diabetic retinopathy: the multi-ethnic study of atherosclerosis. Diabetes Care. 2009 Sep;32(9):1704-9. doi: 10.2337/dc09-0102.
Targher G, Bertolini L, Chonchol M, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia. 2010 Jul;53(7):1341-8. doi: 10.1007/s00125-010-1720-1.
West SD, Groves DC, Lipinski HJ, et al. The prevalence of retinopathy in men with Type 2 diabetes and obstructive sleep apnoea. Diabet Med. 2010 Apr;27(4):423-30. doi: 10.1111/j.1464-5491.2010.02962.x.
Zietz B, Buechler C, Kobuch K, Neumeier M, Schölmerich J, Schäffler A. Serum levels of adiponectin are associated with diabetic retinopathy and with adiponectin gene mutations in Caucasian patients with diabetes mellitus type 2. Exp Clin Endocrinol Diabetes. 2008 Oct;116(9):532-6. doi: 10.1055/s-2008-1058086.
Malachkova NV, Komarovska IV, Kirilyuk ML. Blood glucose level and insulin resistance in patients with type 2 diabetic mellitus, diabetic retinopathy and obesity. Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2017;13(3):129-134. doi: 10.22141/2224-07220.127.116.117.104108.
Malachkova NV, Kirilyuk ML, Komarovska IV. The features of blood pressure in patients with diabetic retinopathy, type 2 diabetes and adiposity. Arhiv oftalmologii Ukrainy. 2017;5(1(7)):32-37. (in Russian).
Malachkova NV, Kirilyuk ML, Komarovska IV. Association between serum resistin level and diabetic retinopathy in obese patients with type 2 diabetes mellitus. Oftalmologicheskii zhurnal. 2017;4(477):9-13. (in Russian).
Serdyuk VN, Ishhenko VA. The content of leptin in the blood of patients with type 2 diabetes mellitus at different stages of diabetic retinopathy. Oftalmologija. 2017;1(06):46-54. (in Russian).
Serdyuk VN, Ishсhenko VA. Morphometric and biochemical clusters of metabolic syndrome in type 2 diabetic patients at different stages of diabetic retinopathy. Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2016;7(79):69-74. doi: 10.22141/2224-0718.104.22.1686.86421.